Fresh capital will push DF-003 through Phase 3 for the rare inflammatory disorder ROSAH syndrome and DF-006 through …
Fresh capital will push DF-003 through Phase 3 for the rare inflammatory disorder ROSAH syndrome and DF-006 through …
Four transactions above $10 billion and 38 acquisitions industrywide signal Big Pharma’s pivot from early bets to buying …
The Coinbase CEO-backed longevity company will advance its epigenetic reprogramming mRNA medicine into Phase I trials for fatty …
Global biopharmaceutical mergers and acquisitions have surged to $106 billion across 201 transactions in 2026, putting the sector …
Interim data in osteogenesis imperfecta show safety remains acceptable, but efficacy thresholds for early stopping were not met
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
New oral vaccine succeeds against multiple cholera strains offering promise for broad use in endemic regions
Funding boost fuels hopes for first disease-modifying treatment in a rare genetic disorder
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Already a subscriber? Log in